by Asa Elmore | Jan 21, 2021 | News, Press Releases
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing...
by Asa Elmore | Jan 5, 2021 | Events, News, Press Releases
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application...
by Asa Elmore | Dec 11, 2020 | News, Press Releases
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug...
by Asa Elmore | Dec 8, 2020 | News, Press Releases
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering South San Francisco, Calif., Dec. 8, 2020 — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
by Asa Elmore | Dec 7, 2020 | News, Press Releases
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock South San Francisco, Calif., Dec. 7, 2020 — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
by Asa Elmore | Dec 7, 2020 | Events, News, Presentations, Press Releases
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting – STRO-001 was generally well-tolerated in patients with late-line...
